MPA and transplant: timing, recurrence, rejection and infection
Every medical claim on this page links to its source. Last updated 15 November 2026. Educational information, not medical advice.
Timing
KDIGO advises waiting for at least six months of complete clinical remission before a transplant. A positive ANCA test on its own should not delay transplant. Centers also consider disease outside the kidneys and the treatment course.1
Can MPA come back?
Yes, sometimes years later. In a French study of adults, 15 of 206 transplant recipients with AAV-related kidney failure (7.3%) had a relapse; in an international study of people diagnosed as children, 8 of 72 (11%) did. These are crude figures from different groups and cannot predict any one person's risk.2,3
Recurrence, rejection or something else?
Recurrent MPA is renewed vasculitis. Rejection is immune injury aimed at the donor kidney. BK virus, other infections, dehydration, medicine toxicity, blockage and chronic scarring can also raise creatinine. The team may use urine tests, drug levels, viral tests, imaging, donor-specific antibody (DSA) tests or a biopsy. Donor-derived cell-free DNA can flag injury in some settings. No single test proves MPA has returned.1,4,5,6
Protecting the new kidney long term
Keep labs on schedule, refill early, check drug, food and supplement interactions with your pharmacist, and keep a written sick-day plan. Coordinate vaccines, skin checks, cervical screening where relevant, and heart and bone care.7,8,9
Medicare has a limited Part B benefit for immunosuppressive drugs after a transplant.10
For researchers and clinicians
Childhood-onset cohort (CJASN 2026): 72 patients, 74% MPA; 8 relapses (11%), median time to first relapse among relapsers 71 months (range 7–182); one relapse led to graft failure. ANCA positivity at transplant was associated with relapse and graft dysfunction in that cohort. French adult cohort (Kidney Int Rep 2025): 15/206 relapses (7.3%). Differences in age, subtype, follow-up and era prevent direct comparison.3,2
Sources
- KDIGO: KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis [doc ref 1]
- Kidney International Reports (2025): Outcomes after kidney transplantation in ANCA-associated renal vasculitis (French multicenter study) [doc ref 3]
- Clinical Journal of the American Society of Nephrology (2026): Kidney transplantation in childhood-onset ANCA-associated vasculitis: long-term outcomes [doc ref 31]
- Transplantation (2024): Second International Consensus Guidelines on the management of BK polyomavirus in kidney transplantation [doc ref 8]
- Transplant International (2023): Post-transplant monitoring of donor-specific antibodies: consensus report [doc ref 32]
- American Society of Transplant Surgeons: Position statement on donor-derived cell-free DNA [doc ref 9]
- American Society of Transplantation: Pediatric transition portal: managing my health care needs [doc ref 11]
- International Pediatric Transplant Association: Management of the paediatric kidney transplant recipient, 2026 [doc ref 8]
- Clinical Transplantation (2026): Common gynecologic issues in patients post-kidney transplantation [doc ref 12]
- CMS: Medicare Part B immunosuppressive drug benefit [doc ref 13]
Links checked 15 November 2026. Full list: all sources.